title: DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.
abstract: Previous studies have shown that blocking DLL4 signaling reduced tumor growth by disrupting productive angiogenesis. We developed selective anti-human and anti-mouse DLL4 antibodies to dissect the mechanisms involved by analyzing the contributions of selectively targeting DLL4 in the tumor or in the host vasculature and stroma in xenograft models derived from primary human tumors. We found that each antibody inhibited tumor growth and that the combination of the two antibodies was more effective than either alone. Treatment with anti-human DLL4 inhibited the expression of Notch target genes and reduced proliferation of tumor cells. Furthermore, we found that specifically inhibiting human DLL4 in the tumor, either alone or in combination with the chemotherapeutic agent irinotecan, reduced cancer stem cell frequency, as shown by flow cytometric and in vivo tumorigenicity studies.
authors: OncoMed Pharmaceuticals Inc., Redwood City, CA 94063, USA. timothy.hoey@oncomed.com
authors: Timothy
authors: T
authors: Hoey
authors: Wan-Ching
authors: WC
authors: Yen
authors: Fumiko
authors: F
authors: Axelrod
authors: Jesspreet
authors: J
authors: Basi
authors: Lucas
authors: L
authors: Donigian
authors: Scott
authors: S
authors: Dylla
authors: Maureen
authors: M
authors: Fitch-Bruhns
authors: Sasha
authors: S
authors: Lazetic
authors: In-Kyung
authors: IK
authors: Park
authors: Aaron
authors: A
authors: Sato
authors: Sanjeev
authors: S
authors: Satyal
authors: Xinhao
authors: X
authors: Wang
authors: Michael F
authors: MF
authors: Clarke
authors: John
authors: J
authors: Lewicki
authors: Austin
authors: A
authors: Gurney
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D051017:Apoptosis Regulatory Proteins / Q000378:metabolism; D002135:Calcium-Binding Proteins; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D018834:Chaperonin 60 / Q000819:agonists / Q000378:metabolism; D004357:Drug Synergism; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism; D036341:Intercellular Signaling Peptides and Proteins / Q000276:immunology*; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors; D000077146:Irinotecan; D008565:Membrane Proteins / Q000037:antagonists & inhibitors; D051379:Mice; D009369:Neoplasms / Q000473:pathology / Q000628:therapy*; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000276:immunology*; D009389:Neovascularization, Pathologic / Q000378:metabolism; D051880:Receptors, Notch / Q000378:metabolism*; D055502:Secondary Prevention; D023041:Xenograft Model Antitumor Assays
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000911:Antibodies, Monoclonal; D000972:Antineoplastic Agents, Phytogenic; D051017:Apoptosis Regulatory Proteins; D002135:Calcium-Binding Proteins; D018834:Chaperonin 60; C424126:DLL4 protein, human; C519665:DLL4 protein, mouse; D051034:Inhibitor of Apoptosis Proteins; D036341:Intercellular Signaling Peptides and Proteins; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D051880:Receptors, Notch; D000077146:Irinotecan; D002166:Camptothecin